Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.63 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.63 |
| ▸ | AXL | P30530 | 1/20 | 0.63 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.56 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | TTK | P33981 | 1/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.56 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30516501 | 1.00 | MKNK1 (0.63) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL22497670 | 0.96 | MKNK1 (0.65) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL28857629 | 0.83 | ALDH1A1 (0.61) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL2377996 | 0.83 | MKNK1 (0.58) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL29898220 | 0.83 | ALDH1A1 (0.61) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL20409462 | 0.83 | MKNK1 (0.58) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL4703894 | 0.83 | MEN1 (0.61) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL12491570 | 0.83 | MKNK1 (0.60) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL11371958 | 0.83 | MKNK1 (0.62) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL28312503 | 0.82 | MKNK1 (0.56) | MKNK1MKNK2MEN1PSIP1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8129396-B2 | 2-[1H-benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors | TELIK, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| CN-102159568-A | 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors | TELIK INC | 2011-08-17 | — | — | CN | disclosed |
| EP-2346856-A1 | 2-[1H-BENZIMIDAZOL-2(3H)-YLIDENE]-2-(PYRIMIDIN-2-YL)ACETAMIDES AND 2-[BENZOTHIAZOL-2(3H)-YLIDENE]-2-(PYRIMIDIN-2-YL)ACETAMIDES AS KINASE INHIBITORS | Telik, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| EP-2336122-A1 | 1-pyrimidinyl- or 1-pyridinyl-2-amino benzimidazole derivatives and related compounds as inhibitors of protein kinases for the treatment of cancer | Vertex Pharmaceuticals Incorporated (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20100081653-A1 | 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors | TELIK, INC. | 2010-04-01 | — | — | US | disclosed |
| WO-2010036873-A1 | 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors | TELIK, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| EP-1557410-B1 | Bacterial gyrase inhibitors and uses thereof | VERTEX PHARMA (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2002060879-A2 | BACTERIAL GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-08-08 | — | — | WO | disclosed |
| US-RE36256-E | ADMINISTERING ARYL-SUBSTITUTED QUINOXALINE DERIVATIVES AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5795889-A | INHIBITING CELL GROWTH WITH ENZYME INHIBITORS FOR SKIN DISORDERS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | disclosed |
| EP-0056260-A1 | Pyridinyl-substituted-benz imidazole derivatives and preparation | STERLING DRUG INC. (US) | 1982-07-21 | — | — | EP | disclosed |
| EP-0055453-A2 | 5-(Pyridinyl)-benzimidazole derivatives and preparation | STERLING DRUG INC. (US) | 1982-07-07 | — | — | EP | disclosed |
| US-4335132-A | 5-(Py-Y)-1H-benzimidazol-2-ols and 5-(Py-Y-)-1H-benzimidazole-2-thiols | STERLING DRUG, INC. (US) | 1982-06-15 | — | — | US | disclosed |
| US-4331671-A | 5-(Pyridinyl)-1H-benzimidazoles and 1-hydroxy-6-(pyridinyl)-1H-benzimidazoles and their cardiotonic use | STERLING DRUG INC. (US) | 1982-05-25 | — | — | US | disclosed |
| US-4297362-A | 4-(3,4-Diaminophenyl)pyridine or salts, and use thereof as cardiotonic | STERLING DRUG INC. (US) | 1981-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081653-A1 | 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors | MAP3K2, MAP4K2, MAP3K12 | MKNK1 97/4885MKNK2 62/4885MEN1 3485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.